
## **Europe Rheumatology**



## **Competitive Benchmarking of Select Rheumatology Sales and Marketing Organizations** Published: December 2017











Based on information derived from primary research conducted by skilled competitive intelligence professionals, this report benchmarks commercial operations for leading companies competing in the dynamic rheumatology specialty market.

Profiles several new entrants in the European rheumatology market, as well as an established product. The products/companies included are:

- Kevzara (Sarilumab) -- Sanofi/Regeneron
- Olumiant (Baricitinib) -- Eli Lilly
- Stelara (Ustekinumab) -- Janssen
- Xeljanz (Tofacitinib) -- Pfizer/Takeda

Allows clients to analyze the commercial functions of the target rheumatology franchises of leading pharmaceutical companies in terms of:

- Sales and Marketing personnel
- MSLs associated with the portfolio
- Product portfolio and promotional priority
- Organizational chart of reporting lines of the personnel listed above

For more information on this report, please contact Joyce Wedemeyer at joyce.wedemeyer@pharmaforce.biz or by phone at (610) 370-2906